Search

Displaying results 4131 - 4140 of 4265 in total
  1. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

  2. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    RESP301 was under investigation in clinical trials for various conditions. It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible...

  3. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  4. Drug

    Alizapride

    go.drugbank.com/drugs/DB01425
    Investigational

    Alizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects. This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, inclu...

  5. Drug

    Thimerosal

    go.drugbank.com/drugs/DB11590
    Approved

    Thiomersal (INN), commonly known in the U.S. as thimerosal, is an organomercury compound. This compound is a well-established and widely used antiseptic and antifungal agent. Developed in 1927, thimerosal has been and is still being used...

  6. Drug

    Exisulind

    go.drugbank.com/drugs/DB06246
    Investigational

  7. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  8. Drug

    PRTX-100

    go.drugbank.com/drugs/DB05947
    Investigational

    PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enabl...

  9. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  10. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).